摘要
目的探讨18F-FDG PET/CT显像在进展期前列腺癌诊断和分期中的临床价值。方法20例临床进展期前列腺癌患者行18F-FDG PET/CT全身显像,同时行B超和骨扫描检查。结果①9例未经治疗者中18F-FDG PET/CT确诊8例;全雄激素阻断治疗(M AB)后前列腺特异性抗原(PSA)值较稳定者及逐渐升高者共5例,PET/CT均准确显示;6例M AB反应良好者,18F-FDG PET/CT示其病灶均无放射性浓聚(即阴性)。②6例盆腔淋巴结转移和6例骨转移者中18F-FDG PET/CT分别发现5例和4例,假阴性者均为M AB后反应良好患者。结论18F-FDG PET/CT显像是评估进展期前列腺癌激素治疗效果的无创性检查方法,有利于未治疗、激素治疗有部分反应及激素难治性进展期前列腺癌的诊断和临床分期。
[Objective] To investigate the clinical value of ^18F-fluorodeoxyglucose （FDG） positron emission tomography （PET/CT） for the diagnosis and staging of clinically advanced prostate cancer. [Methods] Whole body ^18 F-FDG PET/CT imaging with attenuation correction was performed in 20 patients with clinically advanced prostate cancer. They were also assessed by B ultrasound of the abdomen and pelvis, and bone scintigraphy, to evaluate them for metastases. [Results] Eight of the nine untreated patients were positive for radioisotope uptake in the prostate or extraprostatically. The patients were detected prostate cancer by PET/ CT,who were treated hormonally with a detectable but stable PSA（tw0） or treated hormonally while they had rising PSA level （three）. The remaining 6 hormonally responsive patients were negative for FDG uptake in the prostate or any metastatic sites. [Conclusions[ The preliminary study indicates that whole body is F-FDG PET/CT imaging is useful for the diagnosis and staging of advanced prostate cancer in patients who are untreated, partially hormonally responsive, or hormone-refractory,
出处
《山东医药》
CAS
北大核心
2006年第17期15-17,共3页
Shandong Medical Journal
基金
山东省科技发展计划项目(2004GG220214)
